glp-1 reimbursement news Medicaid fuels US coverage of Novo, Lilly weight-loss drugs GLP-1 Uptake by Country: Where

Start your intake Why GLP-1 Safety Data Remains Limited in Lactation GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) were not studied in breastfeeding populations during clinical development

GLP-1 agonists are promising for MASH treatment because they target multiple aspects of the disease, including fat accumulation, inflammation, and insulin resistance, which are all key factors in MASH progression

Gastrointestinal side effects are among the most commonly reported adverse reactions with GLP-1 receptor agonists, and acid reflux (gastro-oesophageal reflux) and heartburn feature prominently in patient experiences

Intellectual property disputes have also unfolded alongside these policy developments